Need an investment idea? Check out Popular Stocks and S2O Stock Screener.

Market Price

1.51 

-0.01 -0.7%

as of Nov 13 '18

52 Week Range:

1.25 1.78


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

International Stem Cell Corporation focuses on the development of therapeutic and biomedical products worldwide. The company's products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cell. It develops various cell types, including neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; liver cells to treat various congenital and acquired liver diseases; and islet cells for the treatment of diabetes. The company also develops, manufactures, and markets skincare products and human cell culture products. Its human cell culture products include human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. The company's human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. It sells skincare products through a Website and professional channels; and human cell culture products through its sales force, OEM partners, and brand distributors. The company was founded in 2001 and is headquartered in Carlsbad, California.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Equity (BVPS) 0.01
1.79
-3.09
15.83
9.62
-3.02
-4.37
-0.53
0.30
0.11
-0.03
growth rate 17,800.0% -100.0% 100.0% -39.2% -100.0% 0.0% 0.0% 100.0% -63.3% -100.0%
Earnings BIT -6.07
-6.57
-7.77
-9.90
-9.17
-9.83
-10.48
-8.56
-4.39
-4.52
-3.77
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Avg.PE -11.80
-1.80
-2.30
-7.00
-8.30
-2.70
-0.67
-0.67
-0.67
-0.67
99.38
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0%
ROA -170.01
-424.68
-409.28
-166.62
-122.59
-204.14
-159.87
-167.29
-36.81
-15.22
-87.27
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ROE -247.37
-429.13
374.70
-337.11
-166.79
-116.27
-276.64
-42.92
-220.77
growth rate 0.0% 100.0% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ROIC -246.96
-702.16
-314.20
-159.86
-107.17
-275.49
-42.68
-218.63
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Cur. Ratio 0.34
0.53
0.61
3.74
1.43
1.18
0.66
0.53
0.54
0.69
0.59
growth rate 55.9% 15.1% 513.1% -61.8% -17.5% -44.1% -19.7% 1.9% 27.8% -14.5%
Quick Ratio 0.12
0.26
0.30
3.21
0.70
0.42
0.36
0.23
0.19
0.19
0.16
growth rate 116.7% 15.4% 970.0% -78.2% -40.0% -14.3% -36.1% -17.4% 0.0% -15.8%
Leverage 7.52
5.22
1.26
1.58
1.78
22.72
4.49
2.05
3.33
growth rate -30.6% -50.9% 25.4% 12.7% 257.3% -80.2% -54.3% 62.4%
Balance Sheet Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Acct.Receivable 0.10
0.10
0.70
0.14
0.27
0.31
0.45
0.54
0.57
0.47
growth rate 0.0% 600.0% -80.0% 95.0% 12.1% 48.0% 19.0% 6.5% -19.0%
Acct.Payable 1.82
1.95
2.07
0.67
1.09
0.84
0.83
growth rate 7.3% 6.3% -67.7% 63.0% -23.0% -1.3%
Cur.Assets 1.00
1.70
7.60
3.02
2.58
4.63
3.62
2.99
2.49
2.86
growth rate 70.0% 347.1% -60.3% -14.5% 79.2% -21.8% -17.3% -16.7% 14.6%
Total Assets 2.20
3.70
9.90
5.74
5.37
7.74
7.18
7.14
7.05
6.86
growth rate 68.2% 167.6% -42.1% -6.4% 44.1% -7.2% -0.6% -1.3% -2.6%
Cash 0.40
0.70
5.80
1.34
0.65
2.29
1.11
0.53
0.11
0.30
growth rate 75.0% 728.6% -77.0% -51.1% 250.6% -51.6% -52.1% -79.3% 176.4%
Inventory 0.40
0.60
0.90
1.27
1.20
1.37
1.52
1.35
1.39
1.31
growth rate 50.0% 50.0% 40.9% -5.4% 14.2% 10.8% -11.1% 3.1% -6.0%
Cur.Liabilities 1.80
2.80
4.50
2.11
2.19
7.02
6.86
5.54
3.60
4.80
growth rate 55.6% 60.7% -53.0% 3.5% 221.0% -2.3% -19.2% -35.1% 33.3%
Liabilities 1.80
4.90
4.50
2.11
2.19
7.02
6.86
5.54
3.60
4.80
growth rate 172.2% -8.2% -53.0% 3.5% 221.0% -2.3% -19.2% -35.1% 33.3%
LT Debt 0.00 0.00 0.00 0.00 0.00 0.00
growth rate
Equity 0.21
0.40
-2.27
5.40
3.62
3.18
0.32
1.59
3.44
2.06
growth rate 90.5% -100.0% 100.0% -32.9% -12.2% -68.5% 402.9% 116.4% -40.1%
Common Shares 35.00
36.00
1.00
2.00
1.00
1.00
1.00
1.00
2.00
3.00
4.00
growth rate 2.9% -97.2% 100.0% -50.0% 0.0% 0.0% 0.0% 100.0% 50.0% 33.3%
Cash Flow Statement Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Capital Expenditures 0.44
0.30
0.70
0.30
0.57
0.20
0.17
0.29
0.04
0.23
0.11
growth rate -31.8% 133.3% -57.1% 88.3% -65.1% -15.2% 73.7% -87.9% 560.0% -51.5%
Cash Dividends 0.00
0.00
0.30
0.40
0.43
0.24
0.00
growth rate 33.3% 7.5% -44.9% -100.0%
Cash From OA -5.23
-4.75
-5.34
-6.95
-6.96
0.00
-6.42
-4.12
-4.20
-2.14
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
FCF per Share -24.14
-20.91
-19.77
-16.75
-15.85
-13.06
-8.99
-6.07
-3.14
-1.36
-0.87
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Sale Purchase of Stock 3.89
7.03
8.12
3.99
1.17
1.52
0.50
growth rate 80.7% 15.6% -50.9% -70.7% 29.9% -67.1%
FCF -6.00
-5.00
-6.00
-8.00
-8.00
-7.00
-7.00
-7.00
-5.00
-5.00
-3.00
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Income Statement Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Sales 0.04
0.50
1.10
1.60
4.53
4.57
6.15
7.02
7.55
7.17
7.46
growth rate 1,192.0% 120.0% 45.5% 183.3% 0.8% 34.6% 14.2% 7.6% -5.1% 4.1%
Op.Income -5.50
-7.20
-10.50
-9.17
-9.83
-10.48
-8.56
-4.39
-4.52
-3.77
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
IBT -6.60
-7.80
-12.70
-9.17
-9.83
-10.48
-12.48
-2.64
-1.08
-6.07
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Net Income -6.60
-7.80
-12.70
-9.17
-9.83
-10.48
-12.48
-2.64
-1.08
-6.07
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
EPS -25.50
-33.00
-39.00
-31.50
-18.00
-19.50
-13.50
-10.34
-2.26
-0.34
-1.46
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Gross Profit 0.00
0.40
0.30
0.80
2.91
3.30
4.50
5.10
5.50
5.22
5.33
growth rate -25.0% 166.7% 264.3% 13.1% 36.7% 13.1% 7.8% -5.0% 2.2%
R&D 1.90
2.20
3.40
4.43
3.60
3.56
5.39
2.71
2.86
2.66
growth rate 15.8% 54.6% 30.4% -18.8% -1.1% 51.3% -49.7% 5.5% -6.9%

Quarterly Statements

Item Name Jun '17 Sep '17 Dec '17 Mar '18 Jun '18
Earnings BIT -1.00
-0.81
-0.99
-1.07
-0.27
growth rate 0.0% 0.0% 0.0% 0.0%
Balance Sheet Jun '17 Sep '17 Dec '17 Mar '18 Jun '18
Acct.Receivable 0.61
0.68
0.47
0.94
1.61
growth rate 13.1% -32.0% 101.9% 71.9%
Acct.Payable 0.39
0.85
0.83
1.61
1.82
growth rate 116.9% -2.1% 94.2% 12.7%
Cur.Assets 2.80
3.13
2.86
3.41
4.34
growth rate 12.1% -8.9% 19.4% 27.3%
Total Assets 7.61
7.95
6.86
7.47
8.42
growth rate 4.5% -13.7% 8.8% 12.7%
Cash 0.30
0.51
0.30
0.45
0.48
growth rate 71.7% -40.4% 47.0% 6.7%
Inventory 1.39
1.35
1.31
1.39
1.68
growth rate -2.7% -3.3% 6.0% 21.4%
Cur.Liabilities 6.02
8.14
4.80
5.83
6.77
growth rate 35.2% -41.0% 21.4% 16.2%
Liabilities 6.02
8.14
4.80
5.83
6.77
growth rate 35.2% -41.0% 21.4% 16.2%
LT Debt
growth rate
Equity 1.59
-0.19
2.06
1.63
1.64
growth rate -100.0% 100.0% -20.6% 0.2%
Common Shares 0.00
0.00
0.01
0.01
0.01
growth rate 0.0% 50.0% 0.0% 0.0%
Cash Flow Statement Jun '17 Sep '17 Dec '17 Mar '18 Jun '18
Capital Expenditures 0.05
0.03
0.02
0.06
0.09
growth rate -44.2% -20.7% 147.8% 61.4%
Cash Dividends
growth rate
Cash From OA -0.76
-0.32
-0.49
-0.05
-0.51
growth rate 0.0% 0.0% 0.0% 0.0%
Sale Purchase of Stock 0.50
0.50
0.50
0.09
growth rate 0.0% 0.0% -82.0%
FCF -0.81
-0.35
-0.52
-0.11
-0.60
growth rate 0.0% 0.0% 0.0% 0.0%
Income Statement Jun '17 Sep '17 Dec '17 Mar '18 Jun '18
Sales 1.76
1.85
1.84
2.63
3.04
growth rate 4.8% -0.3% 42.9% 15.4%
Op.Income -1.00
-0.81
-0.99
-1.07
-0.27
growth rate 0.0% 0.0% 0.0% 0.0%
IBT 0.57
-2.16
-1.39
-0.83
-0.39
growth rate -100.0% 0.0% 0.0% 0.0%
Net Income 0.57
-2.16
-1.39
-0.83
-0.39
growth rate -100.0% 0.0% 0.0% 0.0%
EPS
growth rate
Gross Profit 1.29
1.37
1.22
1.81
1.94
growth rate 6.4% -11.3% 48.4% 7.5%
R&D 0.74
0.67
0.60
0.81
0.45
growth rate -9.3% -9.9% 34.3% -44.3%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

F (0.32)

YOY Growth Grade:

F (0.00)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

Current EPS is negative, therefore value price cannot be calculated.

PE and EPS

Historical Current Forward
PE 99.38 -1.65 -0.99
EPS / Growth 0.0% -0.91

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 16.8%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 0.0% 8.4% 8.4%
Future PE 0.00 8.43 8.43
Future EPS 0.00 0.00 0.00
Value Price
MOS %
0.00
-100.0%
0.00
-100.0%
0.00
-100.0%
MOS Price 0.00 0.00 0.00
IRT 99.00 99.00 99.00

Graham Number:

Current EPS is negative, therefore Graham Number cannot be calculated.
NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.